Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial

This study has been registered with Chinese Clinical Trial Registry (ChiCTR2300070674).

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0302155

Source: PLoS One - May 3, 2024 Category: Biomedical Science Authors: Yu-Hao Lin Source Type: research

More News: Alcoholism | Biomedical Science | China Health | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Eating Disorders & Weight Management | Empagliflozin | Endocrinology | Fatty Liver Disease (FLD) | Insulin | Jardiance | Liver | Liver Disease | Minerals | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | PET Scan | Sodium | Study | Urology & Nephrology